126 related articles for article (PubMed ID: 3487356)
1. The effect of C1 inhibitor upon Hageman factor autoactivation.
Weiss R; Silverberg M; Kaplan AP
Blood; 1986 Jul; 68(1):239-43. PubMed ID: 3487356
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay.
Kaplan AP; Gruber B; Harpel PC
Blood; 1985 Sep; 66(3):636-41. PubMed ID: 3875374
[TBL] [Abstract][Full Text] [Related]
3. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
5. Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa).
Donaldson VH; Mitchell BH; Everson B; Ratnoff OD
Blood; 1990 Feb; 75(4):911-21. PubMed ID: 2302459
[TBL] [Abstract][Full Text] [Related]
6. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein.
Dunn JT; Silverberg M; Kaplan AP
J Biol Chem; 1982 Feb; 257(4):1779-84. PubMed ID: 6915937
[TBL] [Abstract][Full Text] [Related]
7. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
Kaplan AP
Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII).
Silverberg M; Kaplan AP
Blood; 1982 Jul; 60(1):64-70. PubMed ID: 6979361
[TBL] [Abstract][Full Text] [Related]
9. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
Donaldson VH; Harrison RA; Rosen FS; Bing DH; Kindness G; Canar J; Wagner CJ; Awad S
J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500
[TBL] [Abstract][Full Text] [Related]
10. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.
Pixley RA; Schmaier A; Colman RW
Arch Biochem Biophys; 1987 Aug; 256(2):490-8. PubMed ID: 3497611
[TBL] [Abstract][Full Text] [Related]
11. Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor).
Tans G; Rosing J; Griffin JH
J Biol Chem; 1983 Jul; 258(13):8215-22. PubMed ID: 6553053
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.
Ghebrehiwet B; Randazzo BP; Dunn JT; Silverberg M; Kaplan AP
J Clin Invest; 1983 May; 71(5):1450-6. PubMed ID: 6304147
[TBL] [Abstract][Full Text] [Related]
13. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor.
Schousboe I
Eur J Biochem; 2003 Jan; 270(1):111-8. PubMed ID: 12492481
[TBL] [Abstract][Full Text] [Related]
14. The regulation of human factor XIIa by plasma proteinase inhibitors.
Pixley RA; Schapira M; Colman RW
J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
[TBL] [Abstract][Full Text] [Related]
15. Activation of the classical pathway of complement by Hageman factor fragment.
Ghebrehiwet B; Silverberg M; Kaplan AP
J Exp Med; 1981 Mar; 153(3):665-76. PubMed ID: 7252410
[TBL] [Abstract][Full Text] [Related]
16. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S
Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206
[TBL] [Abstract][Full Text] [Related]
17. Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor.
Prograis LJ; Hammer CH; Katusha K; Frank MM
J Immunol Methods; 1987 May; 99(1):113-22. PubMed ID: 3553333
[TBL] [Abstract][Full Text] [Related]
18. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.
Nuijens JH; Huijbregts CC; Eerenberg-Belmer AJ; Abbink JJ; Strack van Schijndel RJ; Felt-Bersma RJ; Thijs LG; Hack CE
Blood; 1988 Dec; 72(6):1841-8. PubMed ID: 3264190
[TBL] [Abstract][Full Text] [Related]
19. Formation and structure of human Hageman factor fragments.
Dunn JT; Kaplan AP
J Clin Invest; 1982 Sep; 70(3):627-31. PubMed ID: 6921203
[TBL] [Abstract][Full Text] [Related]
20. Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments.
Ratnoff OD
Blood; 1981 Jan; 57(1):55-8. PubMed ID: 7448415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
